Medifast's (MED) Sell (D) Rating Reaffirmed at Weiss Ratings

Key Points

• Medifast's stock has been reaffirmed with a "sell (d)" rating by Weiss Ratings, indicating a lack of confidence in its performance.
• The company reported a quarterly EPS of $0.04, surpassing estimates, with revenue of $105.56 million, exceeding analyst expectations.
• Institutional investors hold 95.51% of Medifast's stock, with notable increases in stakes from several hedge funds recently.

Medifast (NYSE:MED - Get Free Report)'s stock had its "sell (d)" rating reissued by equities researchers at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Medifast Trading Up 1.0%

Shares of Medifast stock opened at $14.00 on Wednesday. The company's 50-day moving average price is $13.77 and its two-hundred day moving average price is $13.58. Medifast has a 52 week low of $11.57 and a 52 week high of $21.98. The stock has a market cap of $153.87 million, a PE ratio of 43.75 and a beta of 0.85.

Medifast (NYSE:MED - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The specialty retailer reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.26. The firm had revenue of $105.56 million for the quarter, compared to analysts' expectations of $96.10 million. Medifast had a net margin of 0.76% and a return on equity of 2.00%. Medifast has set its Q3 2025 guidance at -0.600-0.00 EPS. On average, equities analysts predict that Medifast will post 0.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Medifast

Several institutional investors and hedge funds have recently bought and sold shares of MED. GAMMA Investing LLC grew its stake in Medifast by 3,207.2% during the 1st quarter. GAMMA Investing LLC now owns 3,208 shares of the specialty retailer's stock valued at $43,000 after acquiring an additional 3,111 shares in the last quarter. SummerHaven Investment Management LLC grew its stake in Medifast by 2.2% during the 1st quarter. SummerHaven Investment Management LLC now owns 42,073 shares of the specialty retailer's stock valued at $567,000 after acquiring an additional 916 shares in the last quarter. Values First Advisors Inc. grew its stake in Medifast by 3.8% during the 1st quarter. Values First Advisors Inc. now owns 64,228 shares of the specialty retailer's stock valued at $869,000 after acquiring an additional 2,340 shares in the last quarter. Peapod Lane Capital LLC purchased a new position in Medifast during the 1st quarter valued at about $933,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Medifast by 132.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 265,572 shares of the specialty retailer's stock valued at $3,580,000 after acquiring an additional 151,434 shares in the last quarter. Hedge funds and other institutional investors own 95.51% of the company's stock.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.